Clinical Trials Logo

Nausea and Vomiting clinical trials

View clinical trials related to Nausea and Vomiting.

Filter by:

NCT ID: NCT00902733 Completed - Pain Clinical Trials

Nurse-Provided Care or Standard Care in Treating Patients With Pancreatic Cancer

Start date: July 2008
Phase: N/A
Study type: Interventional

RATIONALE: Meeting with a nurse to assess symptoms and quality of life may be more effective than standard care in treating patients with pancreatic cancer. PURPOSE: This clinical trial is studying nurse-provided care to see how well it works compared with standard care in treating patients with pancreatic cancer.

NCT ID: NCT00880191 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy

Start date: April 2009
Phase: Phase 3
Study type: Interventional

RATIONALE: Gabapentin may prevent or reduce delayed nausea and vomiting caused by chemotherapy. It is not yet known whether gabapentin is more effective than a placebo in preventing nausea and vomiting. PURPOSE: This randomized phase III trial is studying the side effects of gabapentin and to see how well it works compared with a placebo in preventing nausea and vomiting in patients receiving chemotherapy.

NCT ID: NCT00748267 Completed - Breast Cancer Clinical Trials

Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer

Start date: August 2008
Phase: N/A
Study type: Interventional

RATIONALE: Hypnosis may be effective in reducing pain and other side effects in women undergoing surgery for breast cancer. PURPOSE: This clinical trial is studying how well hypnosis works in reducing pain and other side effects in women undergoing surgery for breast cancer.

NCT ID: NCT00719173 Completed - Breast Cancer Clinical Trials

Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer

NRR
Start date: August 2005
Phase: Phase 1
Study type: Interventional

RATIONALE: Antiemetic drugs, such as aprepitant, may help lessen or prevent nausea and vomiting in patients undergoing chemotherapy. PURPOSE: This randomized clinical trial is studying aprepitant to see how well it works compared to placebo in preventing nausea and vomiting in patients undergoing chemotherapy for breast cancer.

NCT ID: NCT00590317 Completed - Nausea and Vomiting Clinical Trials

Ondansetron vs Prochlorperazine for Nausea and Vomiting in the Emergency Department

Start date: March 2005
Phase: Phase 2
Study type: Interventional

This study will compare the effect of prochlorperazine and ondansetron for the treatment of nausea and vomiting in the emergency department.

NCT ID: NCT00416689 Completed - Breast Cancer Clinical Trials

Nausea or Vomiting in Patients Who Are Receiving Chemotherapy for Breast Cancer or Lung Cancer

Start date: April 2000
Phase: N/A
Study type: Observational

RATIONALE: Understanding how nausea or vomiting caused by chemotherapy effects a patient's treatment decisions may help doctors plan better cancer treatment and may help patients live more comfortably. PURPOSE: This clinical trial is studying nausea or vomiting in patients who are receiving chemotherapy for breast cancer or lung cancer.

NCT ID: NCT00381862 Completed - Colorectal Cancer Clinical Trials

Phase II Trial Evaluating the Efficacy and Tolerability of Aprepitant & Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting

Start date: June 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy. PURPOSE: This phase II trial is studying how well giving aprepitant together with palonosetron and dexamethasone works in preventing nausea and vomiting caused by chemotherapy in patients receiving chemotherapy for metastatic colorectal cancer.

NCT ID: NCT00343863 Completed - Clinical trials for Stage IIIA Breast Cancer

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

Start date: January 2006
Phase: N/A
Study type: Interventional

RATIONALE: Antiemetic drugs, such as dexamethasone, ondansetron hydrochloride, and palonosetron hydrochloride, may help lessen or prevent nausea and vomiting caused by chemotherapy. PURPOSE: This clinical trial studies how well giving dexamethasone together with ondansetron hydrochloride or palonosetron hydrochloride works in preventing nausea and vomiting in patients receiving doxorubicin hydrochloride and cyclophosphamide for early stage breast cancer

NCT ID: NCT00343460 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

APF530 or Palonosetron Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer

Start date: April 2006
Phase: Phase 3
Study type: Interventional

RATIONALE: Antiemetic drugs, such as APF530, palonosetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients receiving chemotherapy for cancer. It is not yet known whether APF530 is more effective than palonosetron when given together with dexamethasone in preventing nausea and vomiting caused by chemotherapy. PURPOSE: This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.

NCT ID: NCT00310063 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Acupressure in Preventing Nausea and Vomiting in Young Cancer Patients Receiving Chemotherapy

Start date: April 2005
Phase: N/A
Study type: Interventional

RATIONALE: Using acupressure wrist bands to press and stimulate nerves at an acupressure point on the inside of the wrist may help control nausea and vomiting caused by chemotherapy. PURPOSE: This randomized clinical trial is studying how well acupressure works in preventing nausea and vomiting in young cancer patients receiving chemotherapy.